I started my lab at Genentech in June 2007. Being a scientist at Genentech is both exciting and challenging. I enjoy having the privilege of collaborating with many extremely talented colleagues. Together, we harness opportunities to discover basic science and to translate them into innovative medicine that we hope can make a difference in patients’ lives. My lab has interests in understanding the molecular basis of protein-drug interactions using biophysical methods, primarily macromolecular crystallography. At Genentech, our drug discovery efforts aim at tackling protein targets with “atomic precision”. My lab’s research provides structural insights into disease-related biological molecules, and enables structure-based design of small-molecule and antibody drugs.
Prior to Genentech, I was a senior scientist in Structural Biology at Plexxikon, a biotech start-up in Berkeley, CA, where I worked on drug discovery programs for cancer and metabolic disorder. Prior to Plexxikon, I was a staff scientist in the Physical Biosciences Division at Lawrence Berkeley National Laboratory, where I worked on structural genomics projects.
(2012) Proc Natl Acad Sci USA, 109(14):5299-304
My lab’s research activities are focused on the structure determination of drug targets, mostly in the field of oncology and neurodegeneration.
Co-crystallography is vital to structure-based drug design. We collaborate with Medicinal Chemistry and Antibody Engineering on multiple drug discovery projects.
On the basic research side, we have interests in gaining structural insights into biological molecules and molecular assemblies with therapeutic importance. We expect that such knowledge can provide the basis for developing future drug discovery strategy.
We also play a critical role in technology development. An important aspect of my lab’s activity is to improve and implement the high-throughput crystallography platform within the Structural Biology Department.